- NorthStrive Biosciences, wholly owned by PMGC Holdings, transferred EL-32 working cell bank to a US third-party fermentation facility to start manufacturing optimization.
- Program targets higher yield and a scalable process to support IND-enabling work for EL-32.
- Modulant Biosciences, NorthStrive licensee for non-human animal health uses, retained facility to run upstream and downstream process development.
- NorthStrive kept rights for human therapeutic applications while Modulant holds exclusive rights for non-human animal health products.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief on April 12, 2026, and is solely responsible for the information contained therein.
Comments